October 12, 2026 05:59 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Undeclared Emer-GenZ': Shashi Tharoor slams Delhi curbs over CJP protests, calls internet shutdown 'most regressive' | ‘Bharat Mata Ki Jai’, ‘Inquilab Zindabad’: CJP leader Abhijeet Dipke dares Delhi Police to arrest him, says ‘We are not afraid’ | CJP protest crackdown? Abhijeet Dipke, Saurav Das and Ashutosh Ranka detained from inside flight | Dhruv Rathee detained ahead of CJP protests against CEC Gyanesh Kumar as Delhi goes on high alert | ‘Restriction, not complete closure’: Supreme Court questions Delhi shutdown ahead of CJP protest | 'Unwarranted': India hits back at JD Vance over ‘indentured servants’ remark amid US Green Card crackdown | US targets Microsoft, Infosys, Tata in green card crackdown | ‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.